The use of denosumab increases bone mineral density and decreases bone destruction caused by osteoclasts in patients with osteoporosis. This advance will help the treatment and prevention of this disease and other pathologies associated with bone loss.
Denosumab is a monoclonal antibody, which together with the RANKL protein prevents bone destruction
According to the results of a study published in The New England Journal of Medicine, treatment with denosumab, over a period of 6 months, resulted in a decrease in bone resorption along with a rapid increase in bone mineral density. bone. Being useful for the treatment of patients with osteoporosis.
This study included 412 postmenopausal women with low bone mineral density and a mean age of 63 years, who were evaluated for bone regeneration and decreased bone loss.
After choosing a criterion at random, some women received an injection of denosumab, and others a placebo, observing a 3-7% increase in bone mineral density of the lumbar spine in those patients who had been given denosumab. .